Drug Trial Radar · NCT05559125
A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
50
Actual
Start
Nov 8, 2022
Primary completion
Mar 26, 2024
Study completion Mar 26, 2024
Sponsor
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An open-label, single-ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 combined with STSA-1005 in healthy subjects.
Conditions
- Healthy Subject
Interventions
STSA-1002 InjectionDrug
Intravenous injection
STSA-1005 InjectionDrug
Intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram、Vital Signs And Physical Examination Abnormalities.Time frame: 56 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital Of Xingtai Medical College
Xingtai, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.